▲ 29 r/shroomstocksQ3 2026: Psychedelic Drug Development Pipelinepsychedelicalpha.com u/PsilocybinAlpha — 1 month ago
▲ 9 r/shroomstocksField Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yetpsychedelicalpha.com u/PsilocybinAlpha — 1 month ago
▲ 34 r/shroomstocksHHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veteranshhs.gov u/PsilocybinAlpha — 1 month ago
▲ 21 r/shroomstocksA Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatrypsychedelicalpha.com u/PsilocybinAlpha — 2 days ago
▲ 11 r/shroomstocksResearch Analyst / Writer - Psychedelic Drug Development & Clinical Rollout Focus (Open Application)jobs.psychedelicalpha.com u/PsilocybinAlpha — 3 months ago
▲ 15 r/shroomstocksMomentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Racepsychedelicalpha.com u/PsilocybinAlpha — 8 days ago
▲ 5 r/shroomstocksField Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approvalpsychedelicalpha.com u/PsilocybinAlpha — 3 months ago
▲ 35 r/shroomstocksFDA Division of Psychiatry Director Expresses Excitement Around Psychedelicslinkedin.com u/PsilocybinAlpha — 3 months ago
▲ 35 r/shroomstocksCompass Pathways' Chief Medical Officer Guy Goodwin spoke at the American Psychiatric Association's annual meeting earlier this week in San Francisco.linkedin.com u/PsilocybinAlpha — 3 months ago
▲ 28 r/shroomstocks“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelicspsychedelicalpha.com u/PsilocybinAlpha — 3 months ago
▲ 29 r/shroomstocksBreaking: Mike Davis has become Acting Director of FDA’s Center for Drug Evaluation and Research (CDER) following the departure of Tracy Beth Høeglinkedin.com u/PsilocybinAlpha — 3 months ago
▲ 33 r/shroomstocksApril 2026 Psychedelic Bill Rounduppsychedelicalpha.com u/PsilocybinAlpha — 8 days ago